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Hepatic encephalopathy is a complication of liver cirrhosis and is defined as a 
neuropsychiatric disease, with a reversibile character. Besides classical ways of therapy, 
a n  i n c r e a s i n g  i m p o r t a n c e  i s  a t t a c h e d  t o  n u t r i t i o n a l  t h e r a p y  t h a t  i s  a n  e f f e c t i v e  
prevention of the onset and leads to an ease of symptoms in hepathic encephalopathy 
that already exists. After the patient's nutritional status evaluation, the prescription of 
diet that includes adequate protein, calories and vitamins is assessed. The greatest 
importance is attached to the zinc intake as well as branched chain amino acids (BCAA 
therapy) supplementation. It is believed that further development of science in terms of 
nutrigenomics and nutrigenetics will give detailed guidance on further developments 
since the possibility of clinical investigation in these patients is limited. Acta Medica 
Medianae 2012;51(2):39-44. 
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Introduction 
 
Changes in nutrition, as well as changes in 
metabolism of amino acids have an important role 
in the onset of liver cirrhosis complications.  Again, 
malnutrition as a common complication of the end 
stage liver failure (the prevalence of malnutrition in 
liver cirrhosis is estimated to range from 65 %  to 
100%) is an important prognostic factor in terms of 
survival rate, hospitalization rate, posttransplanta-
tional morbidity as well as quality of life. The 
importance of malnutrition is obvious if one 
consideres that patient's nutritional status used to 
be a part of calculationg the Child-Turcotte index. 
However, the index was later reduced to the 
parameters that are easier to assess (clinical signs 
of ascites, encephalopathy and laboratory para-
meters) (1,2).  
However, there is an obvious connection 
between nutrition on the one side and liver cirrhosis 
complications onset on the other side, as well as 
the impact of these complications on the outcome 
of the underlying disease. As the most obvious 
example of this correlation we observed hepatic 
encefalopathy (HE) (3,4). HE is defined as a neuro-
phychiatric disease, with a reversibile character, in 
which base lies the liver damage. It may be 
endogenous, ie. primarily hepatic (occuring as a 
result of fulminant liver damage) and exogenous or 
secondary hepatic (that develops as a consequence 
of portal-systemic shunts existence). There are also 
acute, subacute and chronic HE, and this division 
refers to the speed of the disease development 
(5,6).  
The pathogenesis of HE is multifactorial, but 
in its base lies the damage of metabolic liver 
function and consequent presence of excess toxic 
materies which impact CNS function. HE can 
manifest with the whole specter of psychoneurolo-
gical changes, from barely detectable ones to those 
which dominate in clinical picture (e.g. flapping 
tremor). Mental changes are reflected in changes of 
speech, personality and consciousness. HE evo-
lution passes through four stadia: prodromal 
stadium (signs of a very severe liver disease, a 
consequent change of the general situation, 
changes of patient's personality and damage of 
mental function), threatening coma (with preceeding 
symptoms neurological symptomatology occurs 
with changes in EEG), stupor (uncertain orientation 
of the patient, and contact with the patient is not 
always possible) and coma. In most cases, HE 
diagnosis is assessed by eliminating other 
possibilities of mental status changes. Laboratory 
analyses indicate the existence of liver disease. 
Phychometric tests are also required. Also, the use 
of CT and NMR results can be very helpful in 
diagnostics (5,7-9).  Nutritive therapy of hepatic encephalopathy as a complication of...                                                 Bojana Marković-Živković et al. 
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Patient's nutritional status assessment  
 
Patients with liver disease generally submit to 
normal diet, however, the modification of it, i.e. 
prescribing of a specific diet can have a positive 
impact on disease development and prevention of 
disease complications, especially HE (10,11). We 
have already stated that malnutrition which occurs 
in the clinical picture of liver cirrhosis can speed up 
the development of complications, including the 
possibility of HE rapid emergence.  
Contributing factors to malnutrition develop-
ment in liver cirrhosis are: inadequate diet 
(unintentionally or due to anorexia, nausea, taste 
change, etc.), unadequate synthesis or nutrient 
a b s o r p t i o n  ( d u e  t o  s e v e r e  l i v e r  d a m a g e  a n d  i t s  
consequently reduced capacity, disturbed entero-
hepatic circle, pacreatic insufficiency, cholestasis, 
diarrhea caused by drug consumption), increased 
protein loss (due to complication of cirrhosis, e.g. 
bleeding from gastric or esophageal varices), 
hypermetabolic conditions and increased body 
requirements for energy and proteins, insulin 
resistence, bleeding in GIT, ascites and  infection 
existence (the existence of negative correlation 
between proinflammatory cytokines and nutrient 
intake has been proved) (4).  
Assessment of nutritional status of liver 
cirrhosis patients begins with a questionarre about 
diet habits. Total nutrient intake is assessed and a 
degree of recent weight loss is evaluated. In  case 
of pre-existing liver cirrhosis and existing HE, 
mental status does not allow the use of the correct 
clinical history, so an interview with family 
members is recommended (4).   
In addition to the questionarre, a physical 
examination is conducted, and these two factors 
together make the so-called Subjective Global 
Assessment (SGA). SGA is considered as the most 
valid method, since these parameters are minimally 
affected by fluid retention and ascites presence.  
Anthropometric measurements and bioelectric 
impedanse measurements are even more difficult 
due to the possible ascites presence, while 
malnutrition biomarkers are abnormal due to 
impaired metabolism. However, there are anthro-
pometric parameters independent of ascites 
presence and these are: mid-thigh circumference, 
mid upper arm muscle circumference and skinfold 
thickness (12).  
 
Certain nutrients' effects on the onset of 
hepatic encephalopathy  
 
Former research in the field of dietetics 
concluded that protein intake (from animals and 
plants), branched chain amino-acids, dietary fiber, 
probiotics, vitamins and antioxidants, minerals (zinc 
and magnesium) and L-carnitine have the greatest 
impact on HE (4, 13-15).  
 
Proteins 
 
Clinical studies conducted worldwide have 
shown that the incidence of HE is increased with 
severity of resulting protein malnutrition. Thus, in 
case of a mild protein malnutrition occurrence, 
encephalopathy occurs in about 61% of patients, 
while in severe protein malnutrition it occurs in 
67% of cases (16).  
The conclusion is: if there exists a tolerance 
of protein intake higher that 70 g/day without the 
disturbance of mental status, a diet modification is 
not needed. If patients have a threshold intolerance 
to proteins (60-70 g/day), a diet rich in vegetables 
o r  f i b e r s  i s  r e c o m e n d e d  w i t h  t h e  a i m  o f  H E  
prevention (17).  
Only in patients without tolerance to amount 
of proteins larger than 1g/kg/day, a diet that 
includes only vegetable proteins must be included, 
besides optimal pharmacological therapy, and if 
necessary BCAA (branched chain amino acids-
leucine, isoleucine, valine) enriched formula. 
However, it is important to note that even short 
term complete protein restrictions are strictly 
contraindicated in patients with liver cirrhosis (3).   
Oral BCAA supplementation makes it possible 
for protein-intolerant patients with cirrhosis to 
maintain a positive nitrogen balance without an 
increased risk for encephalopathy onset. However, 
although a somewhat positive impact of supple-
mentation with high levels of BCAA (40-45%) and 
decreased amount of amino acids and methionine 
on patients with HE has been proved, it has no 
impact on nutritional status (17).  
When it comes to heavy protein supple-
mentation, clinical research and practice have 
proved that even patients with severe forms of   
liver cirrhosis tolerate the diet without worsening of 
HE. In theory, protein supplementation represents 
a problem because proteins are being broken down 
to ammonia in the intestinal system, and in a 
normal organism it should be converted to urea. 
Since liver function is damaged, ammonia acts as a 
neurotoxin (11, 18). In brain nerve cells, ammonia 
converts locally to toxic glutamin. Recent research 
has shown that it is possible that glutamin acts as a 
neurotoxin (12, 19, 20). Research on laboratory 
rats has shown that liver failure results in boosting 
levels of ammonia, which entails the production of 
glutamine by skeletal muscle. This shows that 
muscle preservation through proper nutrition is 
crucial in preventing the development of HE (10).  
 
Zinc 
 
Zinc is an element with a very small 
concentration in the body, but it plays an important 
role in the regulation of protein and nitrogen 
metabolism as well as in organism's antioxidative 
defense.  In patients with liver cirrhosis, a reduced 
amount of zinc is common. It should be noted that 
the level of zinc in the body cannot be determined 
solely by measuring its concentration in patients' 
serum since it binds to albumin (4).  
Reduced zinc level correlates with lower 
activity of ornitin transcarbamylase and higher level 
of ammonia in the blood. Also, zinc deficiency leads 
to an impairment of neurotransmiters like gamma 
amino-butiric acid and norepinefrine (21).  Acta Medica Medianae 2012, Vol.51(2)                                      Nutritive therapy of hepatic encephalopathy as a complication of... 
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The causes of zinc deficiency in patients with 
cirrhosis may include: reduced intake through food, 
reduced level of its absorption, reduced hepato-
intestinal extraction, porto-systemic shunt and 
altered protein and amino acids metabolism. 
Deficiency of zinc can damage the activity of urea 
cycle enzymes as well as the activity of glutamine 
synthetase, which results in increased brain 
circulation. Ammonia has an easier penetration into 
brain tissue, causing  further damage and eventual 
emergence or worsening of HE. Zinc deficiency 
results in appetite reduction, immune system 
dysfunction altered taste and smell, anorexia and 
altered patients metabolism (4, 21).  
However, despite the fact that zinc supple-
mentation has a positive influence on zinc 
deficiency in liver cirrhosis, the same therapy did 
not have obvious results in case of already existing 
HE. These results could be the consequence of a 
very scarce research in this area. Besides, different 
dosage and nature of zinc salts were used in the 
conducted research, and also the lenght of 
supplementation varied (4). 
 
Vitamin A 
 
Vitamin A is known as a hepatotoxin when 
given in doses greater than 100 000 IU/day. 
Besides, it is known that alcohol  increases the 
toxicity of vitamin A. Patients with chronic liver 
disease surely need the limitation in vitamin A 
intake (20). 
 
Iron 
 
Patients with fulminant liver disease need an 
advice on iron intake. With iron overintake, it 
concentrates in liver parenchyma instead of being 
eliminated through GIT. About 30% of patients with 
chronic hepatitis C or alcoholic cirrhosis have a 
tendency of secondary chemochromatosis develop-
ment.  
Iron also induces an increased production of 
free radicals and an increased lipid peroxidation 
which leads to organele disfunction, lysosome 
fragility, mitochondrion dysfunction and it all 
eventually leads to cell death. That is why the 
intake of multivitamins without iron is recom-
mended (20).  
 
L- carnitine 
 
Liver is the main site of kethone body 
production which are the products of fatty acids 
oxidation. Fatty acids cannot pass through mito-
chondrial membrane if they are not carried by the 
means of transportational system which includes L-
carnitine (3-hydroxy-4-threemethylaminebutanoate). 
Carnitine is a cofactor of mitochondrial oxidation 
and it prevents the usage of fats with the aim of 
energy production except in  case of starvation (4). 
L-carnitine has a protective role in the organism 
since it is connected with a significant reduction of 
ammoni concentration in blood and brain (22). 
Carnitine deficiency can result in letargy, 
somnolence, confusion and encephalopathy. 
Studies which examined the carnitine status in 
patients with cirrhosis gave different results 
depending on cirrhosis etiology and the severity 
of liver disease (4, 22).  
 
Vitamin B (Thyamine) 
 
The cause of vitamin B1 deficiency in 
cirrhosis includes the decreased intake of 
supplements, low absorbtion and loss of hepatic 
depoes of vitamins. That is how the vitamin B 
supplementation is very important in patients with 
end stage of liver  failure, both caused by alcohol, 
or having other etiology (4).   
 
Other supplements 
 
In patients with liver cirrhosis a decreased 
selenium level is noticed, however, a clear 
connection between this fact and pathogenesis of 
cirrhosis complications has not been found yet (5).  
An impaired hepatobiliary function and porto-
systemic shunt have a consequence of increased 
manganium  concentration in blood as well as 
increased deposition of the same supplement in 
basal structures of the brain, especially in globus 
pallidus. It is considered that manganium toxic 
efects on CNS are connected with the effects of 
glycolytic enzyme glycealdehide-3-phosphate dehy-
drogenase (GAPDH). Researches have shown that 
these effects of manganium are connected with the 
induction of perripheral type of besodyasepine 
receptors. Manganium is connected with the 
increased levels of glutamine and changes in 
dopamine metabolism and it can be connected also 
with other changes in patients with HE, like chara-
cteristic morphologic changes in astrocytes (4, 10).   
Subclinical encephalopathy is present in 
about 75% of patients with liver cirrhosis. It 
influences the way of life and its quality, so it has to 
be treated in the right moment. Research has 
proved that nutritive therapy could be used with 
the aim of alleviating the symptoms and prevention 
as well.  
Patients with HE usually need changes in diet 
with the therapeutic aims, but their optimal 
nutritions needs an adequate intake of proteins, 
calories and vitamins. Patient should be provided 
with nutrients by oral intake or by the nasogastic 
sond, and if it is not possible then with infusion (10, 
11). 
„Mild“ encephalopathy is treated by removing  
the ammonia from the guts. Lactulosis has a key 
role in prevention of HE as well as in the therapy of 
the same condition. Lactulosis per os is still the 
primary therapy in patients with HE, since it 
decreases the level of ammonia in blood (15-45ml, 
per os, 3-4 times a day). A few oral antibiothics can 
be used in the therapy – neomicyn (3-6g/day), 
methronidasole (250 mg/day) or ryphampicine (1-2 
g/day). They decrease the level of gut bacteria 
which produce ammonia. However, they should not Nutritive therapy of hepatic encephalopathy as a complication of...                                                 Bojana Marković-Živković et al. 
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be used for a long period of time, because in that 
way they show their toxic effects. It is useful to 
intake bacteria which do not produce ammonia, like 
Lactobacillus acidophilus and Enterococcus faecium 
(11). 
Replacement of zinc, if it is deficient in an 
organism, is a good choice (3). The connection 
between the onset of encephalopathy and zinc 
deficiency is already proven, however, clinical trials 
with oral supplementation of zinc (600 mg of zinc 
per day) did not yield specific results. Results have 
shown that the influence of zinc on the improve-
ment of liver function is positive, but not to what 
extent and with the help of which mechanism (23, 24).  
Besides pharmacological methods of therapy, 
it has been shown that for now the safest way of 
nutrition therapy with the aim of improving the 
mental status is protein supplementation with 
BCAA. In patients with stable liver cirrhosis there 
was the improvement in their mental status in 
p h y c h o m e t r i c  t e s t s  w h e n  i t  c a m e  t o  n o r m a l  d i e t  
with oral BCAA supplementation (0.25 g/kg/day). It 
has been shown that this kind of therapy lead to 
the improvement of patients' every day functions 
and that phychometric tests were normal. Patients 
who are intolerant to daily intake of proteins (1 
g/kg/day) should be adviced to decrease the intake 
of proteins, but these measures should be delayed. 
In situations when proteins have to be decreased in 
the diet, a nitrogen should be supplemented by 
BCAA oral supplementation (0.25 g/kg/day), with 
further permanent clinical monitoring of the patient. 
Before planning a diet with decreased level of 
proteins we should first have in mind that protein 
intolerance can occur as a transient symptome. It is 
because of these phenomena that protein 
restriction should be advised as soon as possible 
(12).  
There are also special dilutions (the so called 
„comma dilution“) which besides other components 
include BCAA. These are not balanced dilutions and 
they are not recomended as the source of nitrogen 
for parenteral nutrition (14). Justification of BCAA 
use in HE therapy has not been proved yet because 
the worldwide studies have yielded conflicting 
results. Differences resulted from the fact that the 
effects of BCAA therapy are not the same if there 
are different complications of fulminant liver 
cirrhosis (like GI bleeding, sepsis or kidney failure). 
Meta analyses showed that there is a positive effect 
of the usage of BCAA enriched fluids in patients 
with HE, but further and better designed studies are 
needed in order to prove this (12). 
Nutritive therapy application, which includes 
amino acids and nitrogen is well tolerated, with no 
major side effects when it comes to patients 
suffering from cirrhosis. Also, there is no risk of HE 
deterioration, regardless of whether the food is 
administered orally or by tube. Even patients in 
severe stages of alcoholic liver disease tolerate 
plenty of proteins in diet without the appearance or 
worsening of existing HE (12).  
It has not been proven yet what effects the 
nutrients like phosphatidilcholine, S-adenosyl 
methionine (SAM) and saturated fat have on the 
development of complications in the same patient, 
although it is known that they are well tolerated 
after ingestion (10, 11).  
It is believed that further science develop-
ment (nutrigenomics and nutrigenetics) will give 
more detailed guidlines about future therapy 
development (25). 
 
Conclusion 
 
Nutrition modification in patients with cirrhosis 
plays an extremely important role, especially in 
patients with complications such as HE. The 
possibility of following diet in prevention of HE 
should be especially considered, since it is obvious 
that important developments in this field are 
obtained. If it were possible to achieve control over 
the development of such serious liver cirrhosis 
complications using a relatively simple diet 
manipulation, the benefit would be multiple for both 
patients and therapy progress. 
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NUTRITIVNA TERAPIJA HEPATIČNE ENCEFALOPATIJE KAO 
KOMPLIKACIJE CIROZE JETRE 
  
Bojana Marković-Živković, Goran Bjelaković, Danica Marković i Dušica Stojanović 
 
 
Hepatična encefalopatija predstavlja komplikaciju ciroze jetre a definiše se kao 
neuropsihijatrijsko oboljenje, reverzibilnog karaktera. Pored klasičnih načina terapije, 
sve veći značaj se pridaje nutritivnoj terapiji, kojom se vrši efikasna prevencija 
nastanka, kao i ublažavanje simptoma kod već postojeće hepatične encefalopatije. 
Nakon procene nutritivnog statusa bolesnika, pristupa se propisivanju dijete, koja 
podrazumeva adekvatan unos proteina, kalorija i vitamina. Najveći značaj se pridaje 
unosu cinka, kao i suplementaciji amino kiselinama kratkog lanca (BCAA terapija). 
Veruje se da će dalji razvoj nauke, u smislu nutrigenomike i nutrigenetike, dati 
detaljnije smernice o daljim kretanjima, jer je mogućnost kliničkih ispitivanja u slučaju 
ovakvih bolesnika ograničena. Acta Medica Medianae 2012;51(2):39-44. 
 
Ključne reči: hepatična encefalopatija, nutritivni status, nutritivna terapija, 
ciroza jetre 
 